Kevin Lin

Title: Kevin Lin - Innovator in Chemotherapeutic Drug-Conjugated Resins

Introduction

Kevin Lin is an accomplished inventor based in Gilbert, AZ (US). He has made significant contributions to the field of biotechnology, particularly in the development of chemotherapeutic drug-conjugated resins. His innovative work focuses on methods for selectively binding hypermethylated DNA, which has important implications for cancer research and treatment.

Latest Patents

Kevin Lin holds a patent for "Chemotherapeutic drug-conjugated resins and their preferential binding of methylated DNA." This patent describes ligands and methods for selectively binding hypermethylated DNA from a sample. The ligands include a CG-region binding molecule-conjugated resin derived from the aminoglycoside antibiotic amikacin. Furthermore, the CG-region binding molecule may be conjugated to the resin with a crosslinker and/or may be modified with one or more of long chain and short chain alkyl, aryl, piperazinyl, piperidyl, and pyrrolidyl groups. Such ligands are used in methods for contacting a sample to thereby selectively bind hypermethylated DNA.

Career Highlights

Kevin Lin is affiliated with Arizona State University, where he continues to advance his research and innovation in the field of biotechnology. His work has garnered attention for its potential applications in cancer diagnostics and therapeutics.

Collaborations

Some of his notable coworkers include Sudhakar Godeshala and Taraka Sai Pavan Grandhi. Their collaborative efforts contribute to the ongoing research and development in the area of chemotherapeutic applications.

Conclusion

Kevin Lin is a pioneering inventor whose work in chemotherapeutic drug-conjugated resins is paving the way for advancements in cancer treatment. His innovative approaches and collaborations are making a significant impact in the field of biotechnology.